Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

Summary

The purpose of this study is to find out what effects (good and bad) a tumor vaccine (GM.CD40L) used in combination with Nivolumab will have on participants and their cancer. Another purpose of the study is to find out the maximum tolerated dose of nivolumab in combination with GM.CD40L vaccine. Investigators also want to find out if the combination of GM.CD40L and nivolumab can boost the immune system of participants like you, and how their immune system reacts, both before and after the treatment.

Timeline

Start

2018-07

Primary completion

2019-07

Completion

2020-07

Outcome

Outcome not reported

Stopped (Business): “Funding unavailable”

Drugs

Indications